Celgene (NASDAQ:CELG)

biotech

The 5 Most Loved Biotech Stocks of Portfolio Managers

With the market continuing to grind higher, and the memories of the first time the Nasdaq hit 5,000 getting a fair amount of airplay and commentary, the question for most ...
Read Full Story »
research

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
research

Is Revlimid Becoming a Catch-All Cancer Drug?

Celgene Corp. (NASDAQ: CELG) announced that the U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid in conjunction with dexamethasone. This would go toward treating patients that ...
Read Full Story »
biotech

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Since the beginning of the year, there has been a flood of biotech initial public offerings (IPOs) and secondaries, and the market has become so oversaturated that some of the ...
Read Full Story »
Biotechnology word cloud

Short Sellers Look Scared of Big Biotech

The short interest data are out for the January 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Portfolio Managers Love These 5 Biotech Stocks

If there is one industry that had a busy January, it was biotech. In fact, January set an all-time record for issuance and funds raised in the biotech sector, and ...
Read Full Story »
Money background. Close-up.

Is Celgene’s Outlook Good Enough for Investors?

Celgene Corp. (NASDAQ: CELG) reported its fourth-quarter results on Thursday morning. The biotech giant did beat earnings, but investors have to weigh whether it was enough when you consider that ...
Read Full Story »
Biotechnology word cloud

Short Sellers Starting to Gang Up on Biotech

The short interest data are out for the January 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotechs Signals Optimism

The short interest data are out for the December 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
462542665

Celgene Expects to More Than Triple Earnings by 2020

Celgene Corp. (NASDAQ: CELG) provided a preliminary look at its financials for 2014 but also gave its financial outlook for 2015 and far beyond at the Annual J.P. Morgan Healthcare ...
Read Full Story »
Biotechnology word cloud

Wells Fargo’s Top Biotech Stocks for 2015

Looking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo ...
Read Full Story »
buy sell

5 Massive Upside Stocks for 2015

24/7 Wall St. has evaluated many top outside stock picks for 2014 from Wall Street analysts and market pundits. With the Dow Jones Industrial Average and S&P hitting new all-time ...
Read Full Story »
research

RBC’s 5 Top Biotech Stocks to Buy for 2015

As the year 2014 heads toward the finish line, many of the top Wall Street firms are sharpening their pencils and getting top ideas that make good sense for 2015 out ...
Read Full Story »
health care

Merrill Lynch’s Top Health Care Stock Picks for 2015

Merrill Lynch released its report looking forward to 2015 and which stocks it believes will outperform in the health care sector. In 2014, many of these same companies had very ...
Read Full Story »
biotech

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The short interest data are out for the November 28 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »